v3.26.1
Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Schedule of Acquisitions and Cost-Reduction/Productivity Initiatives (Detail) - USD ($)
$ in Millions
3 Months Ended 24 Months Ended 30 Months Ended
Mar. 29, 2026
Mar. 30, 2025
Mar. 29, 2026
Mar. 29, 2026
Restructuring charges/(credits):        
Employee terminations $ 15 $ 384    
Asset impairments 28 173    
Exit costs 6 64    
Restructuring charges/(credits) [1] 49 621    
Integration costs and other [2] 51 57    
Restructuring charges and certain acquisition-related costs 100 678    
Additional depreciation––asset restructuring recorded in Cost of sales [3] 3 4    
Implementation costs [4] 89 50    
Total costs associated with acquisitions and cost-reduction/productivity initiatives 195 673    
Biopharma [Member]        
Restructuring charges/(credits):        
Restructuring charges/(credits) 31 617    
Biopharma [Member] | Manufacturing Optimization Program [Member]        
Restructuring charges/(credits):        
Restructuring charges/(credits) (22) (4) $ 853  
Biopharma [Member] | Realigning Our Cost Base Program [Member]        
Restructuring charges/(credits):        
Restructuring charges/(credits) 47 587   $ 2,900
Other (income)/deductions––net [Member]        
Restructuring charges/(credits):        
Net periodic benefit costs/(credits) recorded in Other (income)/deductions––net 3 (59)    
Cost of sales [Member]        
Restructuring charges/(credits):        
Implementation costs [4] 15 20    
Selling, informational and administrative expenses [Member]        
Restructuring charges/(credits):        
Implementation costs [4] 36 6    
Research and development expenses [Member]        
Restructuring charges/(credits):        
Implementation costs [4] $ 38 $ 24    
[1] Primarily represents cost-reduction initiatives. Amounts associated with our Biopharma segment: (i) charges of $31 million for the three months ended March 29, 2026 (including charges of $47 million for our Realigning our Cost Base Program and credits of $22 million for our Manufacturing Optimization Program) and (ii) charges of $617 million for the three months ended March 30, 2025 (including charges of $587 million for our Realigning our Cost Base Program and credits of $4 million for our Manufacturing Optimization Program).
[2] Represents external, incremental costs directly related to integrating acquired businesses, such as expenditures for consulting and the integration of systems and processes, and certain other qualifying costs.
[3] Represents the impact of changes in the estimated useful lives of assets involved in restructuring actions.
[4] Represents incremental costs directly related to implementing our non-acquisition-related cost-reduction/productivity initiatives.